Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease
Objective: This series of preclinical studies of novel levodopa and carbidopa/levodopa powder formulations delivered by the POD device to rats and non-human primates (NHP) guided…Transcranial Direct Current Stimolation (tDCS) on PD Patients with Freezing of Gait: Preliminary Findings
Objective: The primary endpoint of this study was to evaluate the effect of a transcranial direct current stimulation (tDCS) protocol with anodal stimulation of the…Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients
Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…3 Year QoL Results for PD Patients Receiving DBS: Product Surveillance Registry
Objective: Summarize improvement in quality of life (QoL) by comparing scores from the EQ-5D questionnaire, five level response version (EQ-5D-5L) summary index and visual analog scale (EQ-VAS) obtained for…Directional versus omnidirectional Deep Brain Stimulation for Parkinson’s disease: Results of a prospective, blinded, multi‑center, single-arm crossover study
Objective: To evaluate the efficacy of directional Deep Brain Stimulation (DBS) by assessing the therapeutic window for directional versus omnidirectional stimulation. Background: Directional leads for…Does Gait in Real Life differ between People with Parkinson’s Disease and Healthy Controls?
Objective: We investigated whether: 1) gait in daily life differs in people with Parkinson’s disease (PD) compared to healthy controls (HC), and 2) the length…Parkinson’s disease and intermittent hypoxia training: beneficial or harmful?
Objective: To systematically review the scientific evidence for beneficial or harmful effects of intermittent hypoxia that were used in Parkinson’s disease (PD) in clinical and…Evaluating the Inappropriate Use of Antipsychotics in Parkinson’s Disease Psychosis Patients Within Large National US Healthcare Databases
Objective: To identify Parkinson’s disease psychosis (PDP) treatment characteristics from an aggregate of US national insurer and Medicare databases. Background: Treatment of psychotic symptoms associated…NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson’s Disease: Study Design and Status Update
Objective: To assess the safety and tolerability of nilotinib (150-300 mg once daily) in moderate/advanced Parkinson’s disease (PD). Background: Nilotinib is approved by the FDA…A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results
Objective: The efficacy of isradipine to slow progression of disability in de novo PD participants. Background: There remains no proven therapy to slow progression of…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.